Rx Medicare

Javelin Pharmaceuticals, Inc. (NYSE Amex: JAV – News) today described its initial review of top line results from a Phase III study of Ereska? (intranasal ketamine 30mg). This randomized, multicenter, double-blind, 1:1 placebo-controlled study assessed the safety and analgesic efficacy of repeated doses of Ereska over 6 hours in 259 patients with acute moderate-to-severe pain following orthopedic surgery.

Read More…

Related Posts

• Third Party Reexamination Of Javelin Pharmaceuticals’ Phase III Trial Data For Ereska Yields Statistically Significant Primary Endpoint
• Transdel Pharmaceuticals Announces Positive Phase 3 Study Results For Lead Topical Pain Drug Ketotransdel(R)
• Winston Laboratories, Inc. Announces Positive Top-line Results Of Phase II Clinical Trial Of Civamide Patch
• Positive Phase IIb Results For GSK1838262 (XP13512) Reported For Neuropathic Pain Associated With Post-Herpetic Neuralgia
• Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study For The Treatment Of Postherpetic Neuralgia (PHN)
• AcelRx Announces Positive Phase 2 Results From A Study Of ARX-01 Sufentanil NanoTabs In Treating Post-Operative Pain
• MAP Pharmaceuticals Phase 3 Trial Of Levadex? Migraine Product Candidate Meets All Four Primary Endpoints
• MAP Pharmaceuticals Phase 3 Trial Of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints
• Phase II Results For GSK1838262 (XP13512) Reported For Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
• KAI Pharmaceuticals Initiates Third Phase 2a Study In Program To Develop KAI-1678 For The Treatment Of Neuropathic Pain
• KAI Pharmaceuticals Expands KAI-1678 Development Program, Initiating A Phase 2a Study For Neuropathic Pain
• Cerimon Pharmaceuticals Initiates Phase III Clinical Studies To Evaluate Its Topical Diclofenac Sodium Patch For Mild-to-Moderate Pain
• MAP Pharmaceuticals Announces Completion Of Enrollment In Phase 3 Clinical Trial Of MAP0004 In Patients With Migraine
• EpiCept Announces Positive Results From Phase IIb Trial For EpiCeptTM NP-1
• Phase IIa Clinical Trial Results Relating To CK-1827452 In Patients With Ischemic Cardiomyopathy And Angina

Tags: ereska, intranasal, javelin, ketamine, orthopedic, pain, pharmaceuticals, phase, postoperative, results, trial

This entry was posted on Friday, August 14th, 2009 at 1:08 am and is filed under Analgesics Pain Migraine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.